Human evidence record · Modified GRF(1-29) / 'CJC without DAC'
GHRH(1-29) and D-Ala2 analogue GH-response study
Both peptides stimulated GH; the D-Ala2 analogue was approximately twice as potent as native GHRH(1-29) in this small study.
Quick read
Human evidence record
What this study tells us
This was a human pharmacology or physiology study. It can show what the compound does to measured biological signals, but it may not establish a meaningful clinical benefit.
Who was studied?
Normal men
How many?
n=5
What happened?
Both peptides stimulated GH; the D-Ala2 analogue was approximately twice as potent as native GHRH(1-29) in this small study.
What stops us overclaiming?
Again this is not the tetrasubstituted Mod GRF(1-29) sold as CJC no-DAC.
Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →
Key result
Both peptides stimulated GH; the D-Ala2 analogue was approximately twice as potent as native GHRH(1-29) in this small study.
Study details
Study designHuman dose-response pharmacology
PopulationNormal men
Sample size5
RouteIntravenous bolus
Regimen / exposure0.015 to 0.5 micrograms/kg
DurationSingle-dose challenges
ComparatorVehicle / native GHRH
Primary endpoint / questionGrowth-hormone response
Safety resultTransient flushing occurred at the highest dose; no other side effects were noted.
Key limitationsAgain this is not the tetrasubstituted Mod GRF(1-29) sold as CJC no-DAC.
Registry / identifierPMID 2866496